Alnylam Pharmaceuticals: Bet or Fold?
September 21, 2017 at 15:19 PM EDT
A slew of analysts raised their price targets for Alnylam Pharmaceuticals after the drug maker's stock spiked yesterday following the release of clinical trial data. But one analyst says its time to sell. Here's why.